Skip to main content

Harmony Biosciences Holdings, Inc.

For the period ended Jun 30, 2025. Filed Aug 5, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 5, 2025

HRMY$33.55-0.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Three Months Ended June 30, · ​ · Six Months Ended June 30,
​ · 2025 · 2024 · 2025 · 2024
Net product revenue​$200,489​$172,814​$385,222​$327,429
Cost of product sold​38,153​32,144​70,147​59,628
Gross profit​162,336​140,670​315,075​267,801
Operating expenses:​​​​
Research and development​50,159​63,583​84,699​85,772
Sales and marketing​30,073​28,507​60,784​55,740
General and administrative​33,924​27,224​65,167​52,900
Total operating expenses​114,156​119,314​210,650​194,412
Operating income​48,180​21,356​104,425​73,389
Other expense, net​(193)​37​(469)​(104)
Interest expense​​(3,646)​​(4,404)​​(7,482)​(8,939)
Interest income​5,296​4,705​10,340​9,133
Income before income taxes​49,637​21,694​106,814​73,479
Income tax expense​(9,861)​(10,103)​(21,478)​(23,554)
Net income​$39,776​$11,591​$85,336​$49,925
Unrealized income (loss) on investments​(6)​(63)​173​(236)
Comprehensive income​$39,770​$11,528​$85,509​$49,689
EARNINGS PER SHARE:​​​​
Basic​$0.69​$0.20​$1.49​$0.88
Diluted​$0.68​$0.20​$1.46​$0.87
Weighted average number of shares of common stock - basic​57,469,775​56,802,357​57,390,298​56,786,873
Weighted average number of shares of common stock - diluted​58,427,134​57,541,696​58,468,717​57,571,570

UNAUDITED CONDENSED CONSOLIDATED

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.